• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cerus lands additional $15m in government funding

May 17, 2018 By Sarah Faulkner

CerusCerus (NSDQ:CERS) landed a $15 million amendment to its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and Development Authority, bringing the total potential value of its deal to $201 million.

The expanded agreement is designed to support additional clinical trials of the company’s Intercept blood transfusion technology.

Cerus’ Phase III ReCePI study is slated to assess the safety and efficacy of Intercept-treated red blood cells in patients requiring transfusion for acute blood loss during complex cardiac surgery. The 600-patient trial will randomize participants to receive either conventional red blood cells or those treated with Cerus’ Intercept technology, which inactivates an array of pathogens in an attempt to reduce the risk of transfusion-transmitted infections.

The primary efficacy endpoint of the ReCePI study is the proportion of patients with acute kidney injury within 48 hours following surgery.

The Phase II SCient trial will study the efficacy and safety of Intercept-treated red blood cells in sickle cell disease patients undergoing exchange transfusion, according to Cerus.

“BARDA is an important partner in our mission to establish Intercept as the standard of care for all transfused blood components globally,” chief medical officer Richard Benjamin said in prepared remarks.

“Our collaboration with BARDA provides Cerus with the support and non-dilutive funding anticipated to complete the clinical development, regulatory submission, and commercial scale-up activities for Intercept red blood cells in the U.S.,” he added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Cardiovascular, Clinical Trials, Featured, Funding Roundup, Surgical, Wall Street Beat Tagged With: Cerus Corp.

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS